Literature DB >> 31741949

Role of Toluidine Blue Staining in Suspicious Lesions of Oral Cavity and Oropharynx.

Vidhu Vijayakumar1, Deepa Reghunathan1,2, Balakrishnan Edacheriyan1, Aswin Mukundan1.   

Abstract

Oral cancer; the sixth most common malignancy in the world has one of the lowest 5 year survival rates. This can be attributed mainly to the delay in diagnosis. The purpose of this study was to evaluate the efficacy of vital staining with toluidine blue dye as an adjunct to standard clinical examination to facilitate early detection of malignant lesions of oral cavity and oropharynx. A hospital based diagnostic test accuracy study was carried out on 55 subjects with oral mucosal disorders that included clinically suspicious premalignant or malignant lesions, in the Department of ENT, Academy of Medical Sciences, Pariyaram, Kannur, Kerala over a period of 2 years. All lesions were subjected to detailed clinical examination and toluidine blue staining; and dye retention was recorded with photographs. The results of staining were compared with findings on histopathological examination. The Sensitivity and specificity of toluidine blue test for the detection of malignancy was 92.6 and 67.9% respectively; and the overall diagnostic accuracy was 80%. The result was highly significant with a 'p value' <0.001. The results indicate that toluidine blue staining is a simple, non-invasive technique which can be a valuable adjunct in the diagnostic process of oral and oropharyngeal cancers. © Association of Otolaryngologists of India 2017.

Entities:  

Keywords:  Early diagnosis; Oral and oropharyngeal cancers; Premalignant lesions; Toluidine blue; Vital staining

Year:  2017        PMID: 31741949      PMCID: PMC6848367          DOI: 10.1007/s12070-017-1161-y

Source DB:  PubMed          Journal:  Indian J Otolaryngol Head Neck Surg        ISSN: 2231-3796


  23 in total

1.  Sources and patterns of referrals of oral cancer: role of general practitioners.

Authors:  C Scully; D Malamos; B G Levers; S R Porter; S S Prime
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-06

Review 2.  Global epidemiology of oral and oropharyngeal cancer.

Authors:  Saman Warnakulasuriya
Journal:  Oral Oncol       Date:  2008-09-18       Impact factor: 5.337

3.  The prevalence of oral mucosal lesions in patients visiting a dental school in Southern India.

Authors:  Anuna Laila Mathew; Keerthilatha M Pai; Amar A Sholapurkar; Manoj Vengal
Journal:  Indian J Dent Res       Date:  2008 Apr-Jun

4.  Diagnostic efficiency of toluidine blue with Lugol's iodine in oral premalignant and malignant lesions.

Authors:  Kamarthi Nagaraju; Shiva Prasad; L Ashok
Journal:  Indian J Dent Res       Date:  2010 Apr-Jun

Review 5.  Oral cancer in India: an epidemiologic and clinical review.

Authors:  R Sankaranarayanan
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1990-03

6.  Reliability of toluidine blue application in the detection of oral epithelial dysplasia and in situ and invasive squamous cell carcinomas.

Authors:  M A Onofre; M R Sposto; C M Navarro
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2001-05

Review 7.  Oral cancer. The importance of early diagnosis and treatment.

Authors:  J J Sciubba
Journal:  Am J Clin Dermatol       Date:  2001       Impact factor: 7.403

8.  Recent results of oral cancer research in Kerala, India.

Authors:  R Sankaranarayanan; M K Nair; B Mathew; P Balaram; P Sebastian; S C Dutt
Journal:  Head Neck       Date:  1992 Mar-Apr       Impact factor: 3.147

9.  The usefulness of toluidine staining as a diagnostic tool for precancerous and cancerous oropharyngeal and oral cavity lesions.

Authors:  E Allegra; N Lombardo; L Puzzo; A Garozzo
Journal:  Acta Otorhinolaryngol Ital       Date:  2009-08       Impact factor: 2.124

10.  Acetic acid wash and chemiluminescent illumination as an adjunct to conventional oral soft tissue examination for the detection of dysplasia: a pilot study.

Authors:  Michaell A Huber; Samer A Bsoul; Geza T Terezhalmy
Journal:  Quintessence Int       Date:  2004-05       Impact factor: 1.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.